Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

References

• Yano C, Saeki H, Ishiji T, et al. Impact of disease severity on sleep quality in japanese patients with atopic dermatitis. J Dermatol Sci. 2013;72(2):1–9.
   Web of Science ®Google Scholar
• Farag AK, Roesner LM, Wieschowski S, et al. Specific T cells targeting Staphylococcus aureus fibronectin-binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients. Allergy. 2022;77(4):1245–1253. eng.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548–552.e3. eng.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–151.
   PubMed Web of Science ®Google Scholar
• Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605.
   PubMed Web of Science ®Google Scholar
• Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21–31.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: pathogenesis. Sem Cutan Med Surg. 2017;36(3):100–103.
   PubMed Web of Science ®Google Scholar
• Brown SJ, Elias MS, Bradley M. Genetics in atopic dermatitis: historical perspective and future prospects. Acta Derm Venereol. 2020;100(12):adv00163.
   PubMedGoogle Scholar
• Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20(12):74.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Rinnov MR, Vestergaard C. Disease mechanisms in atopic dermatitis: a review of aetiological factors. Acta Derm Venereol. 2020;100(12):adv00162.
   PubMedGoogle Scholar
• Wollenberg A, Barbarot S, Bieber T, the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zäch S, Taieb A, for the European Task Force on Atopic Dermatitis/EADV Eczema Task Force, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744.
   PubMed Web of Science ®Google Scholar
• Johnson BB, Franco AI, Beck LA, et al. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181-192.
   PubMed Web of Science ®Google Scholar
• Abeck F, Booken N, Schneider S. [Inappropriate systemic therapy in severe atopic dermatitis-severe long-term damage]. Dermatologie (Heidelb). 2022; 73(8):638–640.
   PubMedGoogle Scholar
• OLUMIANT prescribing information: ©lilly USA. LLC. 2022. Available from: https://www.olumiant.com/
   Google Scholar
• Agency EM. Olumiant - baricitinib - An overview of Olumiant and why it is authorised in the EU 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant.
   Google Scholar
• FDA. FDA Approves First Systemic Treatment for Alopecia Areata 2022. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata.
   Google Scholar
• Bieber T, Paller AS, Kabashima K, et al. Atopic Dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022;36(9):1432–1449.
   Google Scholar
• Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity. 2020;52(5):753–766. eng.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. (1440-1592 (Electronic)).
   Google Scholar
• Thyssen JP, Buhl T, Fernández-Peñas P, et al. Baricitinib rapidly improves skin pain resulting in improved quality of life for patients with atopic dermatitis: analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021;11(5):1599–1611.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691–699.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Long-Term efficacy (up to 68 weeks) of baricitinib in combination with topical corticosteroids in adult patients with moderate-to-Severe atopic dermatitis: analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol. 2022. DOI:10.1111/jdv.18816
   Web of Science ®Google Scholar
• Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared to continuous dosing, after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomised substudy from the long-term extension study, BREEZE-AD3. Br J Dermatol. 2021;188(2):208–217.
   Web of Science ®Google Scholar
• Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
   PubMedGoogle Scholar
• Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476–485. eng.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman LA-O, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395–405. eng.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Baghoomian W, Grinich E, et al. The eczema area and severity Index-A practical guide. Dermatitis. 2022;33(3):187–192.
   PubMed Web of Science ®Google Scholar
• Hon KLE, Leung TF, Wong KY, et al. Does age or gender influence quality of life in children with atopic dermatitis? Clin Exp Dermatol. 2008;33(6):705–709. eng.
   PubMed Web of Science ®Google Scholar
• Dawn A, Pa D, Chan YH, et al. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol. 2009;160(3):642–644. eng.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Diepgen T, Bruckner T, et al. Itch intensity evaluated in the german atopic dermatitis intervention study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol. 2008;88(3):234–239.
   PubMed Web of Science ®Google Scholar
• Chamlin SL, Mc L, Fi J, et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. J Am Acad Dermatol. 2008;58(3):415–420.
   PubMedGoogle Scholar
• Chrostowska-Plak D, Reich A, Fau- Szepietowski JC, et al. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):e239–e242.
   PubMed Web of Science ®Google Scholar
• Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31(6):606–614.
   PubMed Web of Science ®Google Scholar
• Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes. 2019;3(1):42.
   PubMedGoogle Scholar
• Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011;6(4):e17520.
   PubMed Web of Science ®Google Scholar
• Yano C, Saeki H, Ishiji T, et al. Impact of disease severity on work productivity and activity impairment in japanese patients with atopic dermatitis. J Dermatol. 2013;40(9):736–739.
   PubMed Web of Science ®Google Scholar
• Gochnauer H, Valdes-Rodriguez R, Cardwell L, et al. The psychosocial impact of atopic dermatitis. Adv Exp Med Biol. 2017;1027:57–69.
   PubMed Web of Science ®Google Scholar
• von Kobyletzki LB, Thomas KS, Schmitt J, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol. 2017;97(1):86–90.
   PubMed Web of Science ®Google Scholar
• Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229.
   PubMed Web of Science ®Google Scholar
• Reich K, Simpson E, Wollenberg A, et al. Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology - Clinical Research and Epidemiology - Abstracts. 2021;141(041):S155.
   Google Scholar
• Nomura T, Wu J, Kabashima K, et al. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840–1852.
   PubMed Web of Science ®Google Scholar
• Kaufman BP, Guttman-Yassky E, AF A. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–357.
   PubMed Web of Science ®Google Scholar
• Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in african American patients is T(H)2/T(H)22-skewed with T(H)1/T(H)17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99–110.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar